Compounds > 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
Page last updated: 2024-10-30

2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Breast Neoplasms

2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one has been researched along with Breast Neoplasms in 171 studies

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source

Breast Neoplasms: Tumors or cancer of the human BREAST.

Research Excerpts

ExcerptRelevanceReference
" Curcumin has potential therapeutic effects against breast cancer through multiple signaling pathways."7.83The inhibition of PI3K and NFκB promoted curcumin-induced cell cycle arrest at G2/M via altering polyamine metabolism in Bcl-2 overexpressing MCF-7 breast cancer cells. ( Akkoç, Y; Arısan, ED; Berrak, Ö; Çoker-Gürkan, A; Obakan-Yerlikaya, P; Palavan-Ünsal, N, 2016)
" Leptin, a key adipokine secreted from adipocytes, shapes the tumor microenvironment, potentiates the migration of breast cancer cells and angiogenesis, and is also involved in EMT."7.83Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2. ( Chen, T; Guo, B; Huang, Y; Ji, F; Jiang, Y; Li, K; Liu, Y; Pang, X; Su, M; Wang, N; Wei, L; Yang, J; Zhang, Z; Zhong, C, 2016)
"The aim of the present study was to investigate the mechanism of the inhibitory effect of luteolin on the proliferation of breast cancer cells induced by epidermal growth factor (EGF) in vitro."7.83Inhibitory effect of luteolin on the proliferation of human breast cancer cell lines induced by epidermal growth factor. ( Sui, JQ; Xie, KP; Xie, MJ, 2016)
"Treatment of breast cancer cells for 6 and 9 h with α-santalol (20, and 40 μM) resulted in statistically significant concentration-dependent down-regulation of survivin."7.81Survivin Down-regulation by α-Santalol Is Not Mediated Through PI3K-AKT Pathway in Human Breast Cancer Cells. ( Bommareddy, A; Brozena, S; Crisamore, K; Dwivedi, C; Fillman, S; Landis, T; Steigerwalt, J; Vanwert, AL, 2015)
" The present study was aimed to investigate the effect of nimbolide on IGF signalling and cell cycle arrest in MCF-7 and MDA-MB-231 breast cancer cell lines."7.80Nimbolide inhibits IGF-I-mediated PI3K/Akt and MAPK signalling in human breast cancer cell lines (MCF-7 and MDA-MB-231). ( Arunakaran, J; Arunkumar, R; Benson, CS; Elumalai, P; Sharmila, G, 2014)
"Lapatinib is highly active against breast cancer with HER2 overexpression in preclinical and clinical settings."7.79Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells. ( Guo, Q; Ma, C; Song, X; Wang, X; Wei, L; Zuo, W, 2013)
"Everolimus, an mTOR inhibitor, showed great clinical efficacy in combination with tamoxifen, letrozole, or exemestane for the treatment of estrogen receptor-positive (ER+) breast cancer."7.79Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. ( Chen, X; Hao, M; Liu, J; Mao, Y; Shen, K; Shen, Y; Sun, X; Wang, J; Zhao, M; Zu, L, 2013)
" We investigated whether the Src/Abl kinase inhibitor dasatinib displays synergy with other agents in molecularly heterogeneous breast cancer cell lines."7.78Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy. ( Corey, SJ; Park, BJ; Whichard, ZL, 2012)
"We have shown that erbB2 altered breast cancer cells are less sensitive to the anti-proliferative effects of metformin than triple negative cells, and have described the differences of molecular mechanisms of metformin action by tumor subtypes."7.77Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. ( Edgerton, SM; Fan, Z; Lind, SE; Liu, B; Thor, AD; Yang, X, 2011)
"To determine the in vitro effects of simultaneously administered LY29400, PD98059, tamoxifen and eicosapentaenoic acid (EPA) on breast cancer cells, and determine their transcutaneous delivery."7.74In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin. ( Davison, Z; Dutkowski, C; Gee, JM; Heard, CM; Nicholson, RI, 2008)
"Indole-3-carbinol (I3C), a dietary chemopreventive compound, induces cell death in human breast cancer cells by modulating activities of Src and epidermal growth factor receptor (EGFR)."7.74Indole-3-carbinol-induced modulation of NF-kappaB signalling is breast cancer cell-specific and does not correlate with cell death. ( Heukers, R; Moiseeva, EP, 2008)
"Despite the success of tamoxifen in treating hormone-responsive breast cancer, its use is limited by the development of resistance to the drug."7.73Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. ( Kilker, RL; Planas-Silva, MD, 2006)
" In this study, we showed that epidermal growth factor (EGF) was a more potent chemoattractant than chemokine SDF-1alpha/CXCL12 for human breast cancer cell MDA-MB-231."7.73Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. ( Chen, L; Gao, P; Ma, D; Oppenheim, JJ; Sun, R; Wang, J; Zhang, N, 2005)
" We undertook this study to determine whether epidermal growth factor (EGF) treatment could produce a signaling cascade resulting in phosphorylation of the forkhead transcription factor FKHR in a breast cancer cell line, MDA-MB-231."7.70Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. ( Brattain, MG; Jackson, JG; Koterba, AP; Kreisberg, JI; Yee, D, 2000)
"Treatment of quiescent MCF-7 human breast cancer cells with either the polypeptide growth factors insulin-like growth factor-I (IGF-I) or epidermal growth factor (EGF), the steroid hormone estradiol (E2) or the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) results in increased steady-state levels of cyclin D1 mRNA and protein."7.70Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells. ( Dufourny, B; Hamelers, IH; Steenbergh, PH; Sussenbach, JS, 2000)
"Breast cancer is the second leading cause of cancer‑related mortality in females worldwide."5.42Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines. ( Lu, J; Ma, R; Sun, D; Tang, J; Wang, L; Wu, J, 2015)
"Human adenocarcinoma MCF7 breast cancer cells were stably depleted of flotillins by means of lentivirus mediated short hairpin RNAs."5.39Phosphatidylinositol 3-Kinase dependent upregulation of the epidermal growth factor receptor upon Flotillin-1 depletion in breast cancer cells. ( Banning, A; John, BA; Kühne, S; Kurrle, N; Meister, M; Ockenga, W; Tikkanen, R; Völlner, F, 2013)
"Chloroquine (CQ) is a 4-aminoquinoline drug used for the treatment of diverse diseases."5.38Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. ( Aryal, S; Cummings, CT; Maycotte, P; Morgan, MJ; Thorburn, A; Thorburn, J, 2012)
"Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis."5.38In vitro mechanisms involved in the regulation of cell survival by lithium chloride and IGF-1 in human hormone-dependent breast cancer cells (MCF-7). ( Babu, SD; Benson, CS; Ramadoss, S; Ravi Sankar, B; Sangeetha, G; Sathyavathy, A; Suganthi, M, 2012)
"Treatment of breast cancer cell lines with a combination of DSF-Cu and LY294002, a pan-PI3K inhibitor, resulted in the significant inhibition of cell growth when compared with either drug alone."5.36Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. ( Chen, D; Chen, W; Cui, QC; Dou, QP; Ethier, SP; Ringler, J; Wu, G; Zhang, H, 2010)
"Pretreatment with losartan (10(-5) M) or LY294002 (50 microM) could significantly suppress these effects of Ang II."5.36Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway. ( Cai, L; Chen, X; Fu, S; Sui, G; Yang, Y; Zhao, Y, 2010)
"Akt promoted breast cancer cell survival because a PI3K inhibitor, LY294002, or transient transfection of a dominant-negative Akt mutant inhibited Akt activity and increased apoptosis."5.31Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. ( Clark, AS; Dennis, PA; Streicher, S; West, K, 2002)
"Human breast cancer cell lines, which express high levels of endogenous Neu receptor, were treated with the anti-Neu antibody, trastuzumab, together with flavopiridol and subject to MTT assay."5.31Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. ( Albanese, C; D'Amico, M; Lee, RJ; Mani, S; Pestell, RG; Wang, C; Wu, K, 2002)
" Leptin, a key adipokine secreted from adipocytes, shapes the tumor microenvironment, potentiates the migration of breast cancer cells and angiogenesis, and is also involved in EMT."3.83Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2. ( Chen, T; Guo, B; Huang, Y; Ji, F; Jiang, Y; Li, K; Liu, Y; Pang, X; Su, M; Wang, N; Wei, L; Yang, J; Zhang, Z; Zhong, C, 2016)
"The aim of the present study was to investigate the mechanism of the inhibitory effect of luteolin on the proliferation of breast cancer cells induced by epidermal growth factor (EGF) in vitro."3.83Inhibitory effect of luteolin on the proliferation of human breast cancer cell lines induced by epidermal growth factor. ( Sui, JQ; Xie, KP; Xie, MJ, 2016)
" Curcumin has potential therapeutic effects against breast cancer through multiple signaling pathways."3.83The inhibition of PI3K and NFκB promoted curcumin-induced cell cycle arrest at G2/M via altering polyamine metabolism in Bcl-2 overexpressing MCF-7 breast cancer cells. ( Akkoç, Y; Arısan, ED; Berrak, Ö; Çoker-Gürkan, A; Obakan-Yerlikaya, P; Palavan-Ünsal, N, 2016)
"Treatment of breast cancer cells for 6 and 9 h with α-santalol (20, and 40 μM) resulted in statistically significant concentration-dependent down-regulation of survivin."3.81Survivin Down-regulation by α-Santalol Is Not Mediated Through PI3K-AKT Pathway in Human Breast Cancer Cells. ( Bommareddy, A; Brozena, S; Crisamore, K; Dwivedi, C; Fillman, S; Landis, T; Steigerwalt, J; Vanwert, AL, 2015)
" The present study was aimed to investigate the effect of nimbolide on IGF signalling and cell cycle arrest in MCF-7 and MDA-MB-231 breast cancer cell lines."3.80Nimbolide inhibits IGF-I-mediated PI3K/Akt and MAPK signalling in human breast cancer cell lines (MCF-7 and MDA-MB-231). ( Arunakaran, J; Arunkumar, R; Benson, CS; Elumalai, P; Sharmila, G, 2014)
"The transforming growth factor beta (TGF-β) signalling pathway is known to control human breast cancer invasion and metastasis."3.79Transforming growth factor-β signalling controls human breast cancer metastasis in a zebrafish xenograft model. ( Drabsch, Y; He, S; Snaar-Jagalska, BE; ten Dijke, P; Zhang, L, 2013)
"Everolimus, an mTOR inhibitor, showed great clinical efficacy in combination with tamoxifen, letrozole, or exemestane for the treatment of estrogen receptor-positive (ER+) breast cancer."3.79Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer. ( Chen, X; Hao, M; Liu, J; Mao, Y; Shen, K; Shen, Y; Sun, X; Wang, J; Zhao, M; Zu, L, 2013)
"Cotylenin A, a plant growth regulator, and rapa-mycin, an inhibitor of the mammalian target of rapamycin, are potent inducers of differentiation in myeloid leukemia cells and also synergistically inhibit the proliferation of several human breast cancer cell lines including MCF-7 in vitro and in vivo."3.79Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells. ( Haranosono, Y; Honma, Y; Kasukabe, T; Kato, N; Okabe-Kado, J, 2013)
"Lapatinib is highly active against breast cancer with HER2 overexpression in preclinical and clinical settings."3.79Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells. ( Guo, Q; Ma, C; Song, X; Wang, X; Wei, L; Zuo, W, 2013)
" Breast cancer resistance protein (BCRP)/ABCG2, a drug efflux pump, confers resistance to multiple anticancer agents such as SN-38 and topotecan."3.78The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation. ( Fukuda, K; Imai, Y; Ueda, Y; Yamagishi, H; Yoshimori, M, 2012)
" We investigated whether the Src/Abl kinase inhibitor dasatinib displays synergy with other agents in molecularly heterogeneous breast cancer cell lines."3.78Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy. ( Corey, SJ; Park, BJ; Whichard, ZL, 2012)
"Capsaicin treatment was previously reported to reduce the sensitivity of breast cancer cells, but not normal MCF10A cells, to apoptosis."3.78Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1. ( Ahn, SG; Jung, SH; Lee, BH; Oh, SH; Yoon, JH, 2012)
"We have shown that erbB2 altered breast cancer cells are less sensitive to the anti-proliferative effects of metformin than triple negative cells, and have described the differences of molecular mechanisms of metformin action by tumor subtypes."3.77Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. ( Edgerton, SM; Fan, Z; Lind, SE; Liu, B; Thor, AD; Yang, X, 2011)
"To determine the in vitro effects of simultaneously administered LY29400, PD98059, tamoxifen and eicosapentaenoic acid (EPA) on breast cancer cells, and determine their transcutaneous delivery."3.74In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin. ( Davison, Z; Dutkowski, C; Gee, JM; Heard, CM; Nicholson, RI, 2008)
"Indole-3-carbinol (I3C), a dietary chemopreventive compound, induces cell death in human breast cancer cells by modulating activities of Src and epidermal growth factor receptor (EGFR)."3.74Indole-3-carbinol-induced modulation of NF-kappaB signalling is breast cancer cell-specific and does not correlate with cell death. ( Heukers, R; Moiseeva, EP, 2008)
" In this study, we showed that epidermal growth factor (EGF) was a more potent chemoattractant than chemokine SDF-1alpha/CXCL12 for human breast cancer cell MDA-MB-231."3.73Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells. ( Chen, L; Gao, P; Ma, D; Oppenheim, JJ; Sun, R; Wang, J; Zhang, N, 2005)
"We determined that Celecoxib analogues are potent inhibitors of P-Akt signalling and kill breast cancer cells that overexpress HER-2."3.73Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. ( Cheang, M; Chen, CS; Dunn, SE; Emerman, J; Gilks, CB; Huntsman, D; Kucab, JE; Lee, C; Pollak, M; Yorida, E; Zhu, J, 2005)
"Despite the success of tamoxifen in treating hormone-responsive breast cancer, its use is limited by the development of resistance to the drug."3.73Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. ( Kilker, RL; Planas-Silva, MD, 2006)
"In this paper the signal transduction pathways evoked by bradykinin (BK) in MCF-7 breast cancer cells were investigated."3.73Protein kinase C (PKC)-delta/-epsilon mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin. ( Greco, S; Marsigliante, S; Storelli, C, 2006)
" Anti-estrogens such as tamoxifen inhibit the growth of ER-positive breast cancers by reducing the expression of estrogen-regulated genes."3.71Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. ( Ali, S; Bhat-Nakshatri, P; Campbell, RA; Constantinidou, D; Nakshatri, H; Patel, NM, 2001)
"We showed earlier that cellular retinol-binding protein (CRBP) expression is downregulated in a subset of human breast cancers."3.71CRBP suppresses breast cancer cell survival and anchorage-independent growth. ( Kuppumbatti, YS; Mira-y-Lopez, R; Nakajo, S; Nakaya, K; Rexer, B, 2001)
" We undertook this study to determine whether epidermal growth factor (EGF) treatment could produce a signaling cascade resulting in phosphorylation of the forkhead transcription factor FKHR in a breast cancer cell line, MDA-MB-231."3.70Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells. ( Brattain, MG; Jackson, JG; Koterba, AP; Kreisberg, JI; Yee, D, 2000)
"Treatment of quiescent MCF-7 human breast cancer cells with either the polypeptide growth factors insulin-like growth factor-I (IGF-I) or epidermal growth factor (EGF), the steroid hormone estradiol (E2) or the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) results in increased steady-state levels of cyclin D1 mRNA and protein."3.70Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells. ( Dufourny, B; Hamelers, IH; Steenbergh, PH; Sussenbach, JS, 2000)
"MDA-MB-231 breast cancer cells were exposed to IGF-1 with various concentrations."2.47PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. ( Chen, Y; Dai, Y; Gu, Y; Qi, X; Sun, B; Zhu, C, 2011)
"ATF3 was observed stronger in breast cancer tissues and cells."1.48Transcription factor ATF3 mediates the radioresistance of breast cancer. ( Chen, Z; Geng, D; Li, S; Sun, M; Zhao, W, 2018)
" The pretreatment, intermittent, and chronic dosing schedules of ospemifene activate naive T-cells, modulate antigen-induced tolerance and reduce tumor-associated, pro-inflammatory cytokines, respectively."1.46Repurposing ospemifene for potentiating an antigen-specific immune response. ( DeGregorio, MW; Kao, CJ; Lin, YC; Phong, B; Vang, DP; Wurz, GT, 2017)
"One hundred sixteen unselected breast tumors were subjected to integrated analysis of phosphoinositide 3-kinase (PI3K) pathway related molecular aberrations by immunohistochemistry, mutation analysis, and gene expression profiling."1.43Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. ( Chen, Y; Dendy, M; Gruvberger-Saal, SK; Hibshoosh, H; Horlings, HM; Isola, J; Jumppanen, M; Lau, YK; Maurer, M; Memeo, L; Parsons, R; Rosen, N; Saal, LH; She, QB; Su, T; van de Vijver, MJ, 2016)
"AZD5363-sensitized Hs578T breast cancer cells displayed reduced levels of phosphorylated glycogen synthase kinase 3 beta (pGSK3β)."1.43Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363-induced Increase in the Level of Phosphorylated AKT. ( Cheon, JH; Choi, AR; Kim, HS; Kim, JH; Woo, YH; Yoon, S, 2016)
"We examined expression of miR-150 in ovarian cancer cells treated with pertuzumab or not."1.42miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation. ( Li, Y; Ma, C; Wang, J; Wuerkenbieke, D, 2015)
"Breast cancer is the second leading cause of cancer‑related mortality in females worldwide."1.42Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines. ( Lu, J; Ma, R; Sun, D; Tang, J; Wang, L; Wu, J, 2015)
"This is the first report showing that breast cancer cells chronically exposed to TRAIL exhibit upregulation of the autophagic activity, indicating that autophagy efficiently protects breast cancer cells from TRAIL."1.42Autophagy facilitates the development of resistance to the tumor necrosis factor superfamily member TRAIL in breast cancer. ( Li, Y; Lv, S; Qi, W; Sun, M; Wang, X; Yang, Q; Zhang, N, 2015)
"First, one DOX resistant breast cancer cell line MCF-7/DOX was successfully established and an increased level of AKR1C3 was observed in the MCF-7/DOX cells compared to the parental MCF-7 cells."1.42Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss. ( Chen, Y; Liu, L; Xu, F; Xu, J; Zhong, T, 2015)
"Diabetes is a risk factor for breast cancer development and is associated with poor prognosis for breast cancer patients."1.42Insulin priming effect on estradiol-induced breast cancer metabolism and growth. ( Cha, SK; Choi, JW; Han, J; Jeong, Y; Kim, HW; Kim, KW; Kim, MK; Park, KH; Phan, AN; Wairagu, PM, 2015)
"Breast cancer is the second leading cause of cancer-related deaths in women."1.40Histone H1 phosphorylation in breast cancer. ( Branson, OE; Chaney, SB; Cheney, CM; Freitas, MA; Harshman, SW; Hoover, ME; Huang, C; Huebner, K; Rosol, TJ; Shapiro, CL; Wysocki, VH, 2014)
"In addition, IL-7δ5 enhanced cancer metastasis and shortened survival time, with increased level changes of activated Akt in nude mice with breast cancer."1.40IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway. ( Chen, J; Pan, D; Pan, L; Peng, Y; Yang, J; Zeng, Z, 2014)
"BRSK1 is a novel tumor suppressor in breast cancer which inversely correlated with Jab1 expression, may involve in the restoring Jab1-induced suppression of p27(Kip1) and may regulate cell cycle through the PI3K/Akt pathway."1.40Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway. ( Chen, JH; Chen, JP; Liu, XB; Ni, QC; Sheng, CY; Wang, H; Wang, QQ; Xu, JF, 2014)
"Livin expression in breast cancer correlated with the clinical stage and axillary lymph node metastasis and could be used as a prognostic marker."1.39Livin promotes progression of breast cancer through induction of epithelial-mesenchymal transition and activation of AKT signaling. ( Chen, L; Li, F; Li, HY; Luo, X; Ren, GS; Su, X; Wang, XY; Yin, X; Zheng, K, 2013)
"Upregulation of PKCη contributes to breast cancer cell growth and targeting either PKCε or PDK1 triggers PKCη downregulation but involves two distinct mechanisms."1.39Upregulation of PKCη by PKCε and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival. ( Basu, A; Outram, SP; Pal, D, 2013)
"Human adenocarcinoma MCF7 breast cancer cells were stably depleted of flotillins by means of lentivirus mediated short hairpin RNAs."1.39Phosphatidylinositol 3-Kinase dependent upregulation of the epidermal growth factor receptor upon Flotillin-1 depletion in breast cancer cells. ( Banning, A; John, BA; Kühne, S; Kurrle, N; Meister, M; Ockenga, W; Tikkanen, R; Völlner, F, 2013)
"Mice-bearing xenografts of MDA-MB-468 breast cancer cells were also used to observe the radiosensitizing effect."1.38Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer. ( Fu, S; Li, P; Li, ZB; Lu, B; Torossian, A; Xu, WC; Zhang, Q, 2012)
"Chloroquine (CQ) is a 4-aminoquinoline drug used for the treatment of diverse diseases."1.38Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. ( Aryal, S; Cummings, CT; Maycotte, P; Morgan, MJ; Thorburn, A; Thorburn, J, 2012)
"We have established several breast cancer cell lines that exhibit a permanent ER-depleted phenotype, induced by shRNA transfection of MCF-7 cells, which afford a useful model for studying acquired endocrine resistance."1.38Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells. ( Al Saleh, S; Khajah, MA; Luqmani, YA; Mathew, PM, 2012)
"Human breast carcinoma cells MCF-7 was cultured in vitro and then exposed to adriamycin with or without LY294002."1.38Effect of LY294002 on adriamycin-induced epithelial-mesenchymal transition in human breast carcinoma cells. ( Cheng, XM; Guo, J; Qi, XH; Qian, YJ; Wang, B; Wu, CJ; Xu, L; Zhao, ML, 2012)
"Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3β (GSK-3β), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis."1.38In vitro mechanisms involved in the regulation of cell survival by lithium chloride and IGF-1 in human hormone-dependent breast cancer cells (MCF-7). ( Babu, SD; Benson, CS; Ramadoss, S; Ravi Sankar, B; Sangeetha, G; Sathyavathy, A; Suganthi, M, 2012)
"In invasive breast cancer, immunohistochemistry revealed the presence of ANXA1 and its receptor, FPR2, in both tumor epithelium and stromal cells."1.37Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2. ( Anderson, RL; Harris, T; Johnstone, CN; Khau, T; Langenbach, SY; Schuliga, M; Stewart, AG, 2011)
"EZH2 inhibition in CAL51 breast cancer cells induces BRCA1 nuclear localization and rescues defects in ploidy and mitosis."1.37Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. ( DuPrie, ML; Gonzalez, ME; Kleer, CG; Krueger, H; Merajver, SD; Toy, KA; Ventura, AC, 2011)
"To examine the effect of PTEN on breast cancer cell proliferation, we expressed PTEN in MDA-MB-468 cells (MDA-MB-468 PTEN) by retroviral infection and tested the cell proliferation rate."1.36PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation. ( Jang, K; Kim, M; Seo, HS; Shin, I, 2010)
"This study showed that two ER+ human breast carcinoma cell lines derived from MCF-7 (MVLN cells) that have acquired under OH-Tamoxifen selection two distinct phenotypes of endocrine resistance both displayed constitutive activation of the PI3K/Akt and MAPK pathways."1.36Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. ( Ben Larbi, S; Bieche, I; Cohen, PA; Dumontet, C; Ghayad, SE; Vendrell, JA, 2010)
"Tamoxifen was below its limit of detection in both Cabosil M5P formulations."1.36In vitro delivery of anti-breast cancer agents directly via the mammary papilla (nipple). ( Davison, Z; Heard, CM; Lee, LM, 2010)
"Treatment of breast cancer cell lines with a combination of DSF-Cu and LY294002, a pan-PI3K inhibitor, resulted in the significant inhibition of cell growth when compared with either drug alone."1.36Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. ( Chen, D; Chen, W; Cui, QC; Dou, QP; Ethier, SP; Ringler, J; Wu, G; Zhang, H, 2010)
"Breast carcinoma is the most common malignancy in women."1.36Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells. ( He, S; Jiang, Y; Liu, F; Liu, S; Xie, Z; Zu, X, 2010)
"Pretreatment with losartan (10(-5) M) or LY294002 (50 microM) could significantly suppress these effects of Ang II."1.36Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway. ( Cai, L; Chen, X; Fu, S; Sui, G; Yang, Y; Zhao, Y, 2010)
"In AZD6244-resistant cancer cells, we observed the impaired nuclear localization of FOXO3a, reduced FOXO3a-mediated transcriptional activity, and decreased the expression of FOXO3a target gene Bim after cell treatment with AZD6244."1.36Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. ( Andreeff, M; Chang, CJ; Du, Y; Engelman, JA; Hortobagyi, GN; Hung, MC; Wang, Y; Wong, KK; Xia, W; Yang, JY, 2010)
"HRG-beta1 stimulation of breast cancer cell line SKBR3 resulted in not only increased cell migration and invasion, upregulation of some mesenchymal markers, and downregulation of epithelial marker, but also upregulation of transcription factor Snail and its nuclear translocation."1.35Heregulin-beta1 promotes metastasis of breast cancer cell line SKBR3 through upregulation of Snail and induction of epithelial-mesenchymal transition. ( Cheng, L; Lang, B; Liu, J; Yao, X; Zha, Z, 2009)
"Whether these breast cancer associated mutations have similar biological effects is largely unknown."1.35Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. ( Dziubinski, M; Ethier, SP; Liu, G; Wu, G; Yang, Z; Zhang, H, 2008)
"SK-BR-3 and BT-474 cells, breast cancer cells that overexpress HER2, expressed higher levels of FASN and ACCalpha compared with MCF-7 and MDA-MB-231 breast cancer cells in which HER2 expression is low."1.34Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. ( Ahn, YH; Kim, KS; Koh, YK; Lee, MY; Moon, JS; Park, BW; Park, SW; Yoon, S, 2007)
"Release of VEGF from a breast cancer cell line (T47D) was quantitated by enzyme linked immunosorbent assay (ELISA)."1.34Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells. ( Bingle, L; Corke, KP; Fang, WG; Gong, LH; Shi, YH; Wang, YX, 2007)
"In the breast cancer model (MCF10A/MCF7) and lung cancer model (BEAS/H1198/H1170) we also found the same result: PRAS40 was constitutively active in H1198/H1170 and MCF7 pre-malignant and malignant cancer cells, but weakly expressed in MCF10A and BEAS normal cell."1.33Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis. ( Huang, B; Porter, G, 2005)
"Fifteen breast cancer cell lines and 92 primary breast tumors (33 with matched normal tissue) were used to check somatic mutation and gene copy number of PIK3CA."1.33Somatic mutation and gain of copy number of PIK3CA in human breast cancer. ( Chatterjee, A; Goldenberg, D; Gollin, SM; Guo, Z; Huang, X; Liu, J; Mambo, E; Sidransky, D; Sukumar, S; Trink, B; Wu, G; Xing, M, 2005)
"Treatment of a ZR-75-1 breast cancer cell line stably transfected with AND-34 plus 2 micromol/L LY294002 or 10 micromol/L NSC23766, a Rac-specific inhibitor, abrogated AND-34-induced resistance to ICI 182,780."1.33AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner. ( Castro, AF; Felekkis, KN; Lerner, A; Narsimhan, RP; Near, R; Quilliam, LA; Zheng, Y, 2005)
"Human breast cancer cell lines, which express high levels of endogenous Neu receptor, were treated with the anti-Neu antibody, trastuzumab, together with flavopiridol and subject to MTT assay."1.31Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. ( Albanese, C; D'Amico, M; Lee, RJ; Mani, S; Pestell, RG; Wang, C; Wu, K, 2002)
"Akt promoted breast cancer cell survival because a PI3K inhibitor, LY294002, or transient transfection of a dominant-negative Akt mutant inhibited Akt activity and increased apoptosis."1.31Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. ( Clark, AS; Dennis, PA; Streicher, S; West, K, 2002)
"We show here that human breast cancer MCF-7 cells, which were prevented from attaching to the substratum and were floating in medium, responded to IGF-I and initiated DNA synthesis."1.31Anchorage-independent activation of mitogen-activated protein kinase through phosphatidylinositol-3 kinase by insulin-like growth factor I. ( Suzuki, K; Takahashi, K, 2000)
"A panel of breast cancer cell lines reflecting the different genetic changes occurring in human breast cancer was analyzed."1.31Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. ( Blancher, C; Harris, AL; Moore, JW; Robertson, N, 2001)
"Forced expression of ErbB2 in breast cancer lines originally expressing low ErbB2 levels augmented receptor expression and sensitized those lines to LY294002- and rapamycin-mediated inhibition of colony formation."1.31ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. ( Hermanto, U; Wang, LH; Zong, CS, 2001)
"Using breast cancer cell lines derived from transgenic mice that overexpress specific oncogene/growth factors in the mammary gland, we show that heregulin but not her2/neu, c-Myc or v-Ha-ras plays a major role in constitutive NF-kappaB activation."1.31Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. ( Bhat-Nakshatri, P; Nakshatri, H; Sweeney, CJ, 2002)
"HER-2/neu-overexpressing breast cancer cell lines were resistant to apoptosis induced by UV treatment and hypoxia, which was suppressed in the presence of the phosphatidylinositol 3-kinase inhibitors LY294002 and wortmannin, indicating a link between AKT activation and stress resistance in HER-2/neu-overexpressing cells."1.31AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. ( Altomare, DA; Bacus, SS; Chin, DM; Farrell, MP; Gudkov, A; Gurova, K; Lyass, L; Testa, JR, 2002)
"Inflammatory breast cancer (IBC) is the most lethal form of locally advanced breast cancer known."1.31Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. ( Bao, LW; Merajver, SD; Miller, FR; Pan, Q; van Golen, KL; Wu, ZF, 2002)
"In many human breast cancers and cultured cell lines, insulin receptor expression is elevated, and insulin, via its own insulin receptor, can stimulate cell growth."1.30Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway. ( Frasca, F; Giorgino, F; Gliozzo, B; Goldfine, ID; Milazzo, G; Papa, V; Pezzino, V; Scalia, P; Sciacca, L; Sung, CK; Vigneri, R, 1998)

Research

Studies (171)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's5 (2.92)18.2507
2000's76 (44.44)29.6817
2010's86 (50.29)24.3611
2020's4 (2.34)2.80

Authors

AuthorsStudies
Zhai, HY1
Zhao, C1
Zhang, N3
Jin, MN2
Tang, SA1
Qin, N2
Kong, DX1
Duan, HQ2
Wang, J5
Xie, K1
Duan, H1
Wang, Y4
Ma, H1
Fu, H1
Zhang, L4
Zheng, Y2
Zeng, L1
Zhang, F1
Che, D1
Cao, Z1
Huang, C2
Xian, L1
Zhang, X4
Zhang, H3
Guo, Z2
Guney Eskiler, G1
Ozturk, M1
Pan, Y1
Wang, X4
Zhang, Y3
Qiao, J1
Sasano, H1
McNamara, K1
Zhao, B1
Zhang, D1
Fan, Y1
Liu, L3
Jia, X1
Liu, M1
Song, S1
Wang, L4
Yi, Y1
Chen, D2
Ao, J1
Zhang, W1
Yi, J1
Ren, X1
Fei, J1
Li, F2
Niu, M1
Chen, H1
Luo, Y2
Luo, Z1
Xiao, ZJ1
Yang, F1
Zhao, N1
Wu, N1
Dong, L1
Meng, F1
Wu, L1
Mitchell, AV1
Block, CJ1
Zhang, B2
Craig, DB1
Jang, H1
Chen, W3
Yang, Q2
Wu, G4
Deng, W1
Zhao, S1
Chen, Y5
Zhao, X1
Sun, S1
Ye, B1
Du, J2
Zhao, W1
Sun, M2
Li, S1
Chen, Z2
Geng, D1
Kozlova, NI1
Morozevich, GE1
Ushakova, NA1
Berman, AE1
Niu, J1
Liang, C1
Zhang, YD1
Liu, FY1
Li, HY2
Xie, SQ1
Sun, H2
Fang, D1
Rabi, T1
Huwiler, A1
Zangemeister-Wittke, U1
Yin, X1
Luo, X1
Su, X1
Wang, XY1
Chen, L2
Zheng, K1
Ren, GS1
Pal, D1
Outram, SP1
Basu, A2
Chen, X2
Zhao, M1
Hao, M1
Sun, X1
Mao, Y1
Zu, L1
Liu, J5
Shen, Y1
Shen, K1
Badinloo, M1
Esmaeili-Mahani, S1
Shan, Y1
Cheng, Y1
Guan, FQ1
Ren, XC1
Feng, X1
Yang, JM1
Shats, I1
Gatza, ML1
Liu, B2
Angus, SP1
You, L1
Nevins, JR1
Yin, C1
Li, H2
Shi, L2
Liu, N1
Sun, Y2
Lu, S1
Liu, Y2
Sun, L1
Li, X2
Qi, Y2
Muthuswami, M1
Ramesh, V1
Banerjee, S1
Viveka Thangaraj, S1
Periasamy, J1
Bhaskar Rao, D1
Barnabas, GD1
Raghavan, S1
Ganesan, K1
Drabsch, Y1
He, S2
Snaar-Jagalska, BE1
ten Dijke, P1
Kurrle, N1
Ockenga, W1
Meister, M1
Völlner, F1
Kühne, S1
John, BA1
Banning, A1
Tikkanen, R1
Tandon, M1
Pratap, J1
Liu, Z1
Zhang, YY1
Zhang, QW1
Zhao, SR1
Wu, CZ1
Cheng, X1
Jiang, CC1
Jiang, ZW1
Liu, H2
Fleming, IN1
Andriu, A1
Smith, TA1
Harshman, SW1
Hoover, ME1
Branson, OE1
Chaney, SB1
Cheney, CM1
Rosol, TJ1
Shapiro, CL1
Wysocki, VH1
Huebner, K1
Freitas, MA1
Cheng, L2
Xia, TS1
Wang, YF1
Zhou, W1
Liang, XQ1
Xue, JQ1
Ding, Q1
Wang, HL1
Jin, MH1
Kong, D1
Jiang, SD1
Yang, J2
Zeng, Z1
Peng, Y1
Chen, J1
Pan, L1
Pan, D1
Elumalai, P1
Arunkumar, R1
Benson, CS2
Sharmila, G1
Arunakaran, J1
Wang, H2
Liu, XB1
Chen, JH1
Wang, QQ1
Chen, JP1
Xu, JF1
Sheng, CY1
Ni, QC1
Wu, J2
Lu, J1
Ma, R1
Sun, D1
Tang, J1
Lv, S1
Qi, W1
Li, Y4
Ma, T1
Yang, L2
Zhang, J1
Liao, YF1
Tzeng, YM1
Hung, HC1
Liu, GY1
Zhong, T1
Xu, F1
Xu, J1
Wairagu, PM1
Phan, AN1
Kim, MK1
Han, J1
Kim, HW1
Choi, JW1
Kim, KW1
Cha, SK1
Park, KH1
Jeong, Y1
Wuerkenbieke, D1
Ma, C2
Huang, G1
Li, M2
Bommareddy, A1
Crisamore, K1
Fillman, S1
Brozena, S1
Steigerwalt, J1
Landis, T1
Vanwert, AL1
Dwivedi, C1
Berrak, Ö1
Akkoç, Y1
Arısan, ED1
Çoker-Gürkan, A1
Obakan-Yerlikaya, P1
Palavan-Ünsal, N1
Mills, SC1
Goh, PH1
Kudatsih, J1
Ncube, S1
Gurung, R1
Maxwell, W1
Mueller, A1
Sui, JQ1
Xie, KP1
Xie, MJ1
Meng, X1
Hu, B1
Hossain, MM1
Chen, G1
She, QB2
Gruvberger-Saal, SK1
Maurer, M1
Jumppanen, M1
Su, T1
Dendy, M1
Lau, YK1
Memeo, L1
Horlings, HM1
van de Vijver, MJ1
Isola, J1
Hibshoosh, H1
Rosen, N1
Parsons, R2
Saal, LH1
Ung, MH1
Wang, GL1
Varn, FS1
Cheng, C1
Wei, L2
Li, K1
Pang, X1
Guo, B1
Su, M1
Huang, Y1
Wang, N1
Ji, F1
Zhong, C1
Zhang, Z1
Jiang, Y2
Chen, T1
Choi, AR1
Kim, JH1
Woo, YH1
Cheon, JH1
Kim, HS1
Yoon, S2
Kao, CJ1
Wurz, GT1
Lin, YC1
Vang, DP1
Phong, B1
DeGregorio, MW1
Jiang, X1
Zhu, S1
Panetti, TS1
Bromberg, ME1
Davison, Z2
Dutkowski, C1
Gee, JM2
Nicholson, RI2
Heard, CM2
Heinonen, H1
Nieminen, A1
Saarela, M1
Kallioniemi, A1
Klefström, J1
Hautaniemi, S1
Monni, O1
Jin, CY1
Kim, GY1
Choi, YH1
Habashy, HO1
Powe, DG1
Staka, CM1
Rakha, EA1
Ball, G1
Green, AR1
Aleskandarany, M1
Paish, EC1
Douglas Macmillan, R1
Ellis, IO1
Zha, Z1
Lang, B1
Yao, X1
Ghayad, SE1
Vendrell, JA1
Ben Larbi, S1
Dumontet, C1
Bieche, I1
Cohen, PA1
Kataoka, Y1
Mukohara, T1
Shimada, H1
Saijo, N1
Hirai, M1
Minami, H1
Li, J2
Song, L1
Xiong, H1
Yan, X1
Yuan, J1
Harfouche, R1
Basu, S1
Soni, S1
Hentschel, DM1
Mashelkar, RA1
Sengupta, S1
No, M1
Choi, EJ1
Kim, IA1
Lee, LM1
Tarkkonen, K1
Ruohola, J1
Härkönen, P1
Liu, F1
Liu, S1
Xie, Z1
Zu, X1
Ringler, J1
Cui, QC1
Ethier, SP2
Dou, QP1
Zhao, Y1
Cai, L1
Yang, Y1
Sui, G1
Fu, S3
Yang, JY1
Chang, CJ1
Xia, W1
Wong, KK1
Engelman, JA1
Du, Y1
Andreeff, M1
Hortobagyi, GN1
Hung, MC1
Wu, Y2
Shang, X1
Sarkissyan, M1
Slamon, D1
Vadgama, JV2
Jang, K1
Kim, M1
Seo, HS1
Shin, I1
Vangamudi, B1
Peng, DF1
Cai, Q1
El-Rifai, W1
Zheng, W1
Belkhiri, A1
Khau, T1
Langenbach, SY1
Schuliga, M1
Harris, T1
Johnstone, CN1
Anderson, RL1
Stewart, AG1
Zhang, XT1
Kang, LG1
Ding, L2
Vranic, S1
Gatalica, Z1
Wang, ZY2
Magloire Ketcha Wanda, GJ1
Njamen, D1
Tagatsing, FM1
Yankep, E1
Vollmer, G1
Gonzalez, ME1
DuPrie, ML1
Krueger, H1
Merajver, SD2
Ventura, AC1
Toy, KA1
Kleer, CG1
Park, S1
Jung, HH1
Park, YH1
Ahn, JS1
Im, YH1
Fu, ZY1
Lv, JH1
Ma, CY1
Yang, DP1
Wang, T1
Fan, Z2
Edgerton, SM1
Yang, X1
Lind, SE1
Thor, AD1
Zhu, C1
Qi, X1
Sun, B1
Dai, Y1
Gu, Y1
Grøvdal, LM1
Kim, J1
Holst, MR1
Knudsen, SL1
Grandal, MV1
van Deurs, B1
Xu, R1
Hu, Z1
Tian, Y1
Zhu, Y1
Gu, L1
Zhou, L1
Lauritzen, G1
Stock, CM1
Lemaire, J1
Lund, SF1
Jensen, MF1
Damsgaard, B1
Petersen, KS1
Wiwel, M1
Rønnov-Jessen, L1
Schwab, A1
Pedersen, SF1
Yoon, JH1
Ahn, SG1
Lee, BH1
Jung, SH1
Oh, SH1
Maycotte, P1
Aryal, S1
Cummings, CT1
Thorburn, J1
Morgan, MJ1
Thorburn, A1
Kang, L1
Park, BJ1
Whichard, ZL1
Corey, SJ1
Li, P2
Zhang, Q2
Torossian, A2
Li, ZB1
Xu, WC2
Lu, B1
Lin, Y1
Cui, H1
Xu, H2
Yue, L1
Jiang, L1
Imai, Y1
Yoshimori, M1
Fukuda, K1
Yamagishi, H1
Ueda, Y2
Ren, Y1
Zhou, X1
Li, G1
Mei, M1
Yao, Z1
Khajah, MA1
Al Saleh, S1
Mathew, PM1
Luqmani, YA1
Doucette, CD1
Hilchie, AL1
Liwski, R1
Hoskin, DW1
Gagliardi, PA1
di Blasio, L1
Orso, F1
Seano, G1
Sessa, R1
Taverna, D1
Bussolino, F1
Primo, L1
Qian, YJ1
Cheng, XM1
Wang, B1
Xu, L1
Wu, CJ1
Zhao, ML1
Qi, XH1
Guo, J1
Suganthi, M1
Sangeetha, G1
Babu, SD1
Sathyavathy, A1
Ramadoss, S1
Ravi Sankar, B1
Berglund, FM1
Weerasinghe, NR1
Davidson, L1
Lim, JC1
Eickholt, BJ1
Leslie, NR1
Zuo, W1
Guo, Q1
Song, X1
Kasukabe, T1
Okabe-Kado, J1
Haranosono, Y1
Kato, N1
Honma, Y1
Alkhalaf, M1
El-Mowafy, A1
Karam, S1
Clark, AS1
West, K1
Streicher, S1
Dennis, PA1
Wu, K1
Wang, C1
D'Amico, M1
Lee, RJ1
Albanese, C1
Pestell, RG1
Mani, S1
Stoica, GE2
Franke, TF2
Wellstein, A2
Czubayko, F1
List, HJ1
Reiter, R2
Morgan, E2
Martin, MB2
Stoica, A2
Liang, K1
Jin, W1
Knuefermann, C1
Schmidt, M1
Mills, GB4
Ang, KK1
Milas, L1
Das, R1
Mahabeleshwar, GH1
Kundu, GC1
Faridi, J1
Fawcett, J1
Roth, RA1
Kawagoe, J1
Ohmichi, M1
Takahashi, T1
Ohshima, C1
Mabuchi, S1
Takahashi, K2
Igarashi, H1
Mori-Abe, A1
Saitoh, M1
Du, B1
Ohta, T1
Kimura, A1
Kyo, S1
Inoue, M1
Kurachi, H1
Moroni, M1
Mueller, S1
Iann, MC1
Winder, AD1
Solit, D1
Basso, A1
Moasser, MM1
Kohn, E1
Lu, Y1
Eder, A1
Fang, X1
Bast, RC3
Gray, J1
Jaffe, R1
Hortobagyi, G1
Yue, W1
Wang, JP1
Conaway, MR1
Santen, RJ1
Radisky, DC1
Wang, F1
Bissell, MJ1
Ostrakhovitch, EA1
Cherian, MG1
Wang, S1
Dumont, N1
Yi, JY1
Koh, Y1
Arteaga, CL1
Lu, D1
Huang, J1
Gaben, AM1
Saucier, C1
Bedin, M1
Redeuilh, G1
Mester, J1
Zheng, L3
Ren, JQ3
Chen, Q2
Zhu, HG3
DeGraffenried, LA1
Fulcher, L1
Friedrichs, WE1
Grünwald, V1
Ray, RB1
Hidalgo, M1
Lynch, L1
Vodyanik, PI1
Boettiger, D1
Guvakova, MA1
Kong, ZL1
Zhang, HP1
Chakravarti, P1
Henry, MK1
Quelle, FW1
Felekkis, KN1
Narsimhan, RP1
Near, R1
Castro, AF1
Quilliam, LA1
Lerner, A1
Shi, YH2
Wang, YX2
Bingle, L2
Gong, LH2
Heng, WJ1
Fang, WG2
Sun, R1
Gao, P1
Ma, D1
Oppenheim, JJ1
Chan, CT1
Metz, MZ1
Kane, SE1
Muscella, A1
Storelli, C2
Marsigliante, S2
Xing, M1
Mambo, E1
Huang, X1
Chatterjee, A2
Goldenberg, D1
Gollin, SM1
Sukumar, S1
Trink, B1
Sidransky, D1
Kucab, JE1
Lee, C1
Chen, CS1
Zhu, J1
Gilks, CB1
Cheang, M1
Huntsman, D1
Yorida, E1
Emerman, J1
Pollak, M1
Dunn, SE2
Huang, B1
Porter, G1
Ripple, MO1
Kalmadi, S1
Eastman, A1
Howells, LM1
Hudson, EA1
Manson, MM1
Greco, S1
Beloueche-Babari, M1
Jackson, LE1
Al-Saffar, NM1
Eccles, SA1
Raynaud, FI1
Workman, P1
Leach, MO1
Ronen, SM1
Frankenberry, KA1
Skinner, H1
Somasundar, P1
McFadden, DW1
Vona-Davis, LC1
Liu, X1
Shi, Y1
Giranda, VL1
Scuric, Z1
Chakrabarti, R1
Marzo, E1
Shen, D1
Kilker, RL1
Planas-Silva, MD1
Lee, MY1
Park, SW1
Moon, JS1
Koh, YK1
Ahn, YH1
Park, BW1
Kim, KS1
Moiseeva, EP1
Heukers, R1
Corke, KP1
Liu, G1
Dziubinski, M1
Yang, Z1
Phillips, TM1
Kim, K1
Vlashi, E1
McBride, WH1
Pajonk, F1
Das, S1
Banerji, A1
Frei, E1
Kogai, T1
Ohashi, E1
Jacobs, MS1
Sajid-Crockett, S1
Fisher, ML1
Kanamoto, Y1
Brent, GA1
Dufourny, B2
Alblas, J1
van Teeffelen, HA1
van Schaik, FM1
van der Burg, B1
Steenbergh, PH2
Sussenbach, JS2
Gliozzo, B1
Sung, CK1
Scalia, P1
Papa, V1
Frasca, F1
Sciacca, L1
Giorgino, F1
Milazzo, G1
Goldfine, ID1
Vigneri, R1
Pezzino, V1
Niemann, C1
Brinkmann, V1
Spitzer, E1
Hartmann, G1
Sachs, M1
Naundorf, H1
Birchmeier, W1
Asslan, R1
Pradines, A1
Pratx, C1
Allal, C1
Favre, G1
Le Gaillard, F1
Maus, MV1
Reilly, SC1
Clevenger, CV1
Monno, S1
Newman, MV1
Cook, M1
Lowe, WL1
Le, XF2
McWatters, A2
Wiener, J1
Wu, JY1
Gingras, S1
Côté, S1
Simard, J1
Lobenhofer, EK1
Huper, G1
Iglehart, JD1
Marks, JR1
Suzuki, K1
Vadlamudi, R1
Bae, DS1
Kumar, R1
Hamelers, IH1
Jackson, JG1
Kreisberg, JI1
Koterba, AP1
Yee, D1
Brattain, MG1
Campbell, RA1
Bhat-Nakshatri, P2
Patel, NM1
Constantinidou, D1
Ali, S1
Nakshatri, H2
Torres, JV1
Oh, JS1
Cykert, DM1
Barrett, JC1
Simpson, L1
Liaw, D1
Hennessy, I1
Oliner, J1
Christians, F1
Ng, T1
Parsons, M1
Hughes, WE1
Monypenny, J1
Zicha, D1
Gautreau, A1
Arpin, M1
Gschmeissner, S1
Verveer, PJ1
Bastiaens, PI1
Parker, PJ1
Bachelder, RE1
Crago, A1
Chung, J1
Wendt, MA1
Shaw, LM1
Robinson, G1
Mercurio, AM1
Blancher, C1
Moore, JW1
Robertson, N1
Harris, AL1
Sliva, D1
Rizzo, MT1
English, D1
Kuppumbatti, YS1
Rexer, B1
Nakajo, S1
Nakaya, K1
Mira-y-Lopez, R1
Hermanto, U1
Zong, CS1
Wang, LH1
Hu, Y1
Dragowska, WH1
Wallis, A1
Duronio, V1
Mayer, L1
Sweeney, CJ1
Bacus, SS1
Altomare, DA1
Lyass, L1
Chin, DM1
Farrell, MP1
Gurova, K1
Gudkov, A1
Testa, JR1
Duan, R1
Xie, W1
McDougal, A1
Safe, S1
van Golen, KL1
Bao, LW1
Pan, Q1
Miller, FR1
Wu, ZF1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies[NCT00770263]Phase 146 participants (Actual)Interventional2009-05-31Completed
Phase I Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Resistant Solid Malignancies[NCT00703170]Phase 128 participants (Actual)Interventional2008-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Breast Neoplasms

ArticleYear
PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:11

    Topics: Animals; Breast Neoplasms; Chromones; Female; Humans; Insulin-Like Growth Factor I; Lymphatic Metast

2011
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
    Seminars in oncology, 2003, Volume: 30, Issue:5 Suppl 16

    Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Chromones; Clinical Trials as Topic; D

2003
Effects of recombinant erythropoietin on breast cancer-initiating cells.
    Neoplasia (New York, N.Y.), 2007, Volume: 9, Issue:12

    Topics: Adenocarcinoma; Amyloid Precursor Protein Secretases; Breast Neoplasms; Cell Adhesion; Cell Division

2007

Other Studies

168 other studies available for 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one and Breast Neoplasms

ArticleYear
Alkaloids from Pachysandra terminalis inhibit breast cancer invasion and have potential for development as antimetastasis therapeutic agents.
    Journal of natural products, 2012, Jul-27, Volume: 75, Issue:7

    Topics: Alkaloids; Antineoplastic Agents; Breast Neoplasms; Drugs, Chinese Herbal; Female; Humans; Molecular

2012
Isolation and characterization of diterpene glycosides from Siegesbeckia pubescens.
    Bioorganic & medicinal chemistry letters, 2017, 04-15, Volume: 27, Issue:8

    Topics: Antineoplastic Agents, Phytogenic; Asteraceae; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Di

2017
3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K/AKT/mTOR signaling pathway.
    Life sciences, 2021, Nov-15, Volume: 285

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones;

2021
Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
    Cellular signalling, 2022, Volume: 91

    Topics: BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Chromones; Female; Humans; Morpholines; Phosphati

2022
Estradiol-Induced MMP-9 Expression via PELP1-Mediated Membrane-Initiated Signaling in ERα-Positive Breast Cancer Cells.
    Hormones & cancer, 2020, Volume: 11, Issue:2

    Topics: Breast Neoplasms; Cell Line, Tumor; Chromones; Co-Repressor Proteins; Dose-Response Relationship, Dr

2020
Transcriptional suppression of AMPKα1 promotes breast cancer metastasis upon oncogene activation.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 04-07, Volume: 117, Issue:14

    Topics: AMP-Activated Protein Kinases; Animals; Breast; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; C

2020
TNFR2 promotes Adriamycin resistance in breast cancer cells by repairing DNA damage.
    Molecular medicine reports, 2017, Volume: 16, Issue:3

    Topics: Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Chromones; DNA Damage; Doxorubicin; Drug Resista

2017
Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells.
    International journal of oncology, 2017, Volume: 51, Issue:4

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Chromosomes, Human

2017
MICAL1 facilitates breast cancer cell proliferation via ROS-sensitive ERK/cyclin D pathway.
    Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Proliferation; Chromones; Cyclin D; Cyt

2018
Transcription factor ATF3 mediates the radioresistance of breast cancer.
    Journal of cellular and molecular medicine, 2018, Volume: 22, Issue:10

    Topics: Activating Transcription Factor 3; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation;

2018
Implication of Integrin α2β1 in Proliferation and Invasion of Human Breast Carcinoma and Melanoma Cells: Noncanonical Function of Akt Protein Kinase.
    Biochemistry. Biokhimiia, 2018, Volume: 83, Issue:6

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromones; Extracellular Sign

2018
Suppression of epidermal growth factor receptor-mediated β-catenin nuclear accumulation enhances the anti-tumor activity of phosphoinositide 3-kinase inhibitor in breast cancer.
    Cell biology international, 2019, Volume: 43, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Breast Neoplasms; Cell Proliferation;

2019
AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells.
    Molecular carcinogenesis, 2014, Volume: 53, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pr

2014
Livin promotes progression of breast cancer through induction of epithelial-mesenchymal transition and activation of AKT signaling.
    Cellular signalling, 2013, Volume: 25, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adult; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Mov

2013
Upregulation of PKCη by PKCε and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival.
    Biochimica et biophysica acta, 2013, Volume: 1830, Issue:8

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chr

2013
Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Molecular cancer research : MCR, 2013, Volume: 11, Issue:10

    Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea

2013
Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
    Fundamental & clinical pharmacology, 2014, Volume: 28, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms;

2014
Triticuside A, a dietary flavonoid, inhibits proliferation of human breast cancer cells via inducing apoptosis.
    Nutrition and cancer, 2013, Volume: 65, Issue:6

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Caspase 3; Caspase 7; Caspase 9; Cell Li

2013
FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
    Cancer research, 2013, Oct-01, Volume: 73, Issue:19

    Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Breast Neoplasms; Cell Proliferatio

2013
Nir1 promotes invasion of breast cancer cells by binding to chemokine (C-C motif) ligand 18 through the PI3K/Akt/GSK3β/Snail signalling pathway.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Calcium-Binding Proteins; Cell Line, Tumo

2013
Breast tumors with elevated expression of 1q candidate genes confer poor clinical outcome and sensitivity to Ras/PI3K inhibition.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Breast Neoplasms; Cell Line, Tumor; Chromones; Chromosome Mapping; Chromosomes, Human, Pair 1; Clust

2013
Transforming growth factor-β signalling controls human breast cancer metastasis in a zebrafish xenograft model.
    Breast cancer research : BCR, 2013, Nov-07, Volume: 15, Issue:6

    Topics: Animals; Benzamides; Breast Neoplasms; Chromones; Dioxoles; Dipeptides; Disease Models, Animal; Drug

2013
Phosphatidylinositol 3-Kinase dependent upregulation of the epidermal growth factor receptor upon Flotillin-1 depletion in breast cancer cells.
    BMC cancer, 2013, Dec-05, Volume: 13

    Topics: Breast Neoplasms; Cell Proliferation; Chromones; Endocytosis; Epidermal Growth Factor; ErbB Receptor

2013
Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells.
    Breast cancer research : BCR, 2014, Jan-30, Volume: 16, Issue:1

    Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Core Bi

2014
3-Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl-1 through the PI3K/Akt signaling pathway.
    Anti-cancer drugs, 2014, Volume: 25, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Apoptosis; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Sur

2014
Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
    Breast cancer research and treatment, 2014, Volume: 144, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Chromon

2014
Histone H1 phosphorylation in breast cancer.
    Journal of proteome research, 2014, May-02, Volume: 13, Issue:5

    Topics: Amino Acid Sequence; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chromatograph

2014
The apoptotic effect of D Rhamnose β-hederin, a novel oleanane-type triterpenoid saponin on breast cancer cells.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Breast Neoplasms; Caspase

2014
Synthesis and antimetastatic effects of E-salignone amide derivatives.
    Drug development research, 2014, Volume: 75, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Movement; Chromones; Female; Humans; Molec

2014
IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway.
    Histochemistry and cell biology, 2014, Volume: 142, Issue:4

    Topics: Alternative Splicing; Animals; Breast Neoplasms; Cadherins; Cell Proliferation; Cell Survival; Chrom

2014
Nimbolide inhibits IGF-I-mediated PI3K/Akt and MAPK signalling in human breast cancer cell lines (MCF-7 and MDA-MB-231).
    Cell biochemistry and function, 2014, Volume: 32, Issue:5

    Topics: beta Catenin; Breast Neoplasms; Cell Line, Tumor; Chromones; Down-Regulation; Female; G1 Phase Cell

2014
Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.
    Experimental and molecular pathology, 2014, Volume: 97, Issue:2

    Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Chromones; COP9 Signalosome Complex; Cytoplas

2014
Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines.
    Molecular medicine reports, 2015, Volume: 11, Issue:2

    Topics: Abietanes; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Breast Neopl

2015
Autophagy facilitates the development of resistance to the tumor necrosis factor superfamily member TRAIL in breast cancer.
    International journal of oncology, 2015, Volume: 46, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Breast Neoplasms; Cell Survival; Chloroquine; Chromones

2015
MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
    Oncology reports, 2015, Volume: 33, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tu

2015
Dibenzoylmethane, hydroxydibenzoylmethane and hydroxymethyldibenzoylmethane inhibit phorbol-12-myristate 13-acetate‑induced breast carcinoma cell invasion.
    Molecular medicine reports, 2015, Volume: 11, Issue:6

    Topics: Acetophenones; Benzopyrans; Breast Neoplasms; Cell Movement; Chalcones; Chromones; Female; Humans; K

2015
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN loss.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, Volume: 69

    Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Apoptosis; Blotting, Wester

2015
Insulin priming effect on estradiol-induced breast cancer metabolism and growth.
    Cancer biology & therapy, 2015, Volume: 16, Issue:3

    Topics: Breast Neoplasms; Butadienes; Cell Proliferation; Chromones; Diabetes Complications; Diabetes Mellit

2015
miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.
    Archives of gynecology and obstetrics, 2015, Volume: 292, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Ov

2015
The role of EphB4 and IGF-IR expression in breast cancer cells.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:5

    Topics: Breast Neoplasms; Cell Differentiation; Cell Movement; Chromones; Female; Gene Expression Regulation

2015
Survivin Down-regulation by α-Santalol Is Not Mediated Through PI3K-AKT Pathway in Human Breast Cancer Cells.
    Anticancer research, 2015, Volume: 35, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones;

2015
The inhibition of PI3K and NFκB promoted curcumin-induced cell cycle arrest at G2/M via altering polyamine metabolism in Bcl-2 overexpressing MCF-7 breast cancer cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2016, Volume: 77

    Topics: Acetyltransferases; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cell Su

2016
Cell migration towards CXCL12 in leukemic cells compared to breast cancer cells.
    Cellular signalling, 2016, Volume: 28, Issue:4

    Topics: Breast Neoplasms; Chemokine CXCL12; Chemotaxis; Chromones; Female; Humans; Janus Kinase 2; Jurkat Ce

2016
Inhibitory effect of luteolin on the proliferation of human breast cancer cell lines induced by epidermal growth factor.
    Sheng li xue bao : [Acta physiologica Sinica], 2016, Feb-25, Volume: 68, Issue:1

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; Epidermal Growth Factor; ErbB Rec

2016
ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation.
    International journal of oncology, 2016, Volume: 49, Issue:2

    Topics: ADAM17 Protein; Animals; Benzamides; Breast Neoplasms; Chromones; Diphenylamine; ErbB Receptors; Fem

2016
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
    BMC cancer, 2016, 08-02, Volume: 16

    Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Animals; Breast Neoplasms; Chromones; Class I Phosph

2016
Application of pharmacologically induced transcriptomic profiles to interrogate PI3K-Akt-mTOR pathway activity associated with cancer patient prognosis.
    Oncotarget, 2016, Dec-20, Volume: 7, Issue:51

    Topics: Algorithms; Androstadienes; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Chromon

2016
Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2.
    Journal of experimental & clinical cancer research : CR, 2016, 10-21, Volume: 35, Issue:1

    Topics: Animals; Breast Neoplasms; Carrier Proteins; Cell Line, Tumor; Cell Movement; Chromones; Epithelial-

2016
Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363-induced Increase in the Level of Phosphorylated AKT.
    Anticancer research, 2016, Volume: 36, Issue:11

    Topics: Breast Neoplasms; Cell Line, Tumor; Chromones; Drug Synergism; Enzyme Inhibitors; Heterocyclic Compo

2016
Repurposing ospemifene for potentiating an antigen-specific immune response.
    Menopause (New York, N.Y.), 2017, Volume: 24, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Calmodulin; Cancer Vaccin

2017
Formation of tissue factor-factor VIIa-factor Xa complex induces activation of the mTOR pathway which regulates migration of human breast cancer cells.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:1

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Chromones; Factor VIIa; Factor Xa; Female; Humans

2008
In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin.
    Pharmaceutical research, 2008, Volume: 25, Issue:11

    Topics: Administration, Cutaneous; Animals; Breast Neoplasms; Cell Line, Tumor; Chromones; Cyclooxygenase 2;

2008
Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer.
    BMC genomics, 2008, Jul-24, Volume: 9

    Topics: Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chromones; Gene Expressi

2008
Induction of apoptosis by aqueous extract of Cordyceps militaris through activation of caspases and inactivation of Akt in human breast cancer MDA-MB-231 Cells.
    Journal of microbiology and biotechnology, 2008, Volume: 18, Issue:12

    Topics: Apoptosis; Breast Neoplasms; Caspases; Cell Line, Tumor; Cell Proliferation; Chromones; Cordyceps; C

2008
Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
    Breast cancer research and treatment, 2010, Volume: 119, Issue:2

    Topics: Adult; Antigens, CD; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carcinoma

2010
Heregulin-beta1 promotes metastasis of breast cancer cell line SKBR3 through upregulation of Snail and induction of epithelial-mesenchymal transition.
    Cancer letters, 2009, Jul-18, Volume: 280, Issue:1

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Chemotaxis; Chromones; Enzyme Inhibitors; Epithel

2009
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    International journal of cancer, 2010, Jan-15, Volume: 126, Issue:2

    Topics: Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Prolife

2010
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms;

2010
Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1.
    Oncogene, 2009, Sep-10, Volume: 28, Issue:36

    Topics: Blotting, Western; Breast Neoplasms; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation;

2009
Nanoparticle-mediated targeting of phosphatidylinositol-3-kinase signaling inhibits angiogenesis.
    Angiogenesis, 2009, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cells, Cultured;

2009
Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance.
    Cancer biology & therapy, 2009, Volume: 8, Issue:24

    Topics: Antineoplastic Agents; Breast Neoplasms; Butadienes; Cell Cycle; Cell Line, Tumor; Chromones; Dose-R

2009
In vitro delivery of anti-breast cancer agents directly via the mammary papilla (nipple).
    International journal of pharmaceutics, 2010, Mar-15, Volume: 387, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Chromones; D

2010
Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells.
    Growth factors (Chur, Switzerland), 2010, Volume: 28, Issue:4

    Topics: Angiogenesis Modulating Agents; Animals; Blotting, Western; Breast Neoplasms; Butadienes; Cell Line;

2010
Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
    Oncology reports, 2010, Volume: 23, Issue:5

    Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tra

2010
Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo.
    Cancer research, 2010, May-15, Volume: 70, Issue:10

    Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Chromones; Class I Phosphatidylinositol 3-Kinases; Copp

2010
Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway.
    Journal of cellular physiology, 2010, Volume: 225, Issue:1

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Breast Neoplasms; Cell Cycle; Cell Line, Tu

2010
Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer.
    Cancer research, 2010, Jun-01, Volume: 70, Issue:11

    Topics: Animals; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Chlor

2010
FOXO1A is a target for HER2-overexpressing breast tumors.
    Cancer research, 2010, Jul-01, Volume: 70, Issue:13

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms;

2010
PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
    Oncology reports, 2010, Volume: 24, Issue:3

    Topics: Antineoplastic Agents; Breast Neoplasms; Butadienes; Cell Cycle; Cell Line, Tumor; Cell Proliferatio

2010
t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer.
    Molecular cancer, 2010, Sep-13, Volume: 9

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Cyclin D1; Dopamin

2010
Annexin-1 signals mitogen-stimulated breast tumor cell proliferation by activation of the formyl peptide receptors (FPRs) 1 and 2.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2011, Volume: 25, Issue:2

    Topics: Annexin A1; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; Enzyme Inhibitors; Fe

2011
A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.
    Oncogene, 2011, Feb-17, Volume: 30, Issue:7

    Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Prolif

2011
Regulation of CD1, Ki-67, PCNA mRNA expression, and Akt activation in estrogen-responsive human breast adenocarcinoma cell line, MCF-7 cells, by griffonianone C, an isoflavone derived from Millettia griffoniana.
    Pharmaceutical biology, 2011, Volume: 49, Issue:4

    Topics: Adenocarcinoma; Antigens, CD1; Breast; Breast Neoplasms; Cell Line, Tumor; Chromones; Enzyme Inhibit

2011
Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.
    Cancer research, 2011, Mar-15, Volume: 71, Issue:6

    Topics: Active Transport, Cell Nucleus; Androstadienes; Blotting, Western; BRCA1 Protein; Breast Neoplasms;

2011
ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression.
    Biochemical and biophysical research communications, 2011, Apr-22, Volume: 407, Issue:4

    Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Enzyme Activation; Enzyme Inhibitors; Epi

2011
Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-кB pathway.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2011, Volume: 65, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chromones; Epirubicin; Female;

2011
Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.
    Cell cycle (Georgetown, Tex.), 2011, Sep-01, Volume: 10, Issue:17

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell

2011
EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Cellular signalling, 2012, Volume: 24, Issue:1

    Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; ErbB Receptors; Erlotinib Hydrochloride;

2012
PI3K and ERK-induced Rac1 activation mediates hypoxia-induced HIF-1α expression in MCF-7 breast cancer cells.
    PloS one, 2011, Volume: 6, Issue:9

    Topics: Breast Neoplasms; Butadienes; Cell Hypoxia; Cell Line, Tumor; Chromones; Extracellular Signal-Regula

2011
The Na+/H+ exchanger NHE1, but not the Na+, HCO3(-) cotransporter NBCn1, regulates motility of MCF7 breast cancer cells expressing constitutively active ErbB2.
    Cancer letters, 2012, Apr-28, Volume: 317, Issue:2

    Topics: Amiloride; Benzamides; Breast Neoplasms; Cation Transport Proteins; Cell Adhesion; Cell Line, Tumor;

2012
Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
    Biochemical pharmacology, 2012, Mar-15, Volume: 83, Issue:6

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; Breast Neoplasms; Caffeine; Capsaicin;

2012
Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy.
    Autophagy, 2012, Feb-01, Volume: 8, Issue:2

    Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line

2012
Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; Estradiol; Est

2012
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
    Cancer letters, 2012, Jul-01, Volume: 320, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Butadienes; Cel

2012
Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.
    International journal of radiation oncology, biology, physics, 2012, Jul-01, Volume: 83, Issue:3

    Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chromones; ErbB Receptors; Female; G1 Phase;

2012
Jolkinolide B induces apoptosis in MDA-MB-231 cells through inhibition of the PI3K/Akt signaling pathway.
    Oncology reports, 2012, Volume: 27, Issue:6

    Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Prolifera

2012
The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Oncology reports, 2012, Volume: 27, Issue:6

    Topics: Androstadienes; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-

2012
PTEN activation sensitizes breast cancer to PI3-kinase inhibitor through the β-catenin signaling pathway.
    Oncology reports, 2012, Volume: 28, Issue:3

    Topics: Adenoviridae; Animals; Antineoplastic Agents; beta Catenin; Breast Neoplasms; Cell Line, Tumor; Cell

2012
Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478, an epidermal growth factor receptor inhibitor, in breast cancer cells.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell

2012
Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Benzamides; Breast Neoplasms; Cell Movement; Cell Proliferation; Chemokine CCL5; Chromones; Collagen

2012
Piperine, a dietary phytochemical, inhibits angiogenesis.
    The Journal of nutritional biochemistry, 2013, Volume: 24, Issue:1

    Topics: Alkaloids; Angiogenesis Inhibitors; Animals; Aorta; Benzodioxoles; Breast Neoplasms; Cell Movement;

2013
3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner.
    Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:8

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Anoikis; Breast Neoplasms; Cell Proliferation

2012
Effect of LY294002 on adriamycin-induced epithelial-mesenchymal transition in human breast carcinoma cells.
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2012, Volume: 34, Issue:4

    Topics: Antigens, CD; Breast Neoplasms; Cadherins; Chromones; Doxorubicin; Epithelial-Mesenchymal Transition

2012
In vitro mechanisms involved in the regulation of cell survival by lithium chloride and IGF-1 in human hormone-dependent breast cancer cells (MCF-7).
    Toxicology letters, 2012, Oct-17, Volume: 214, Issue:2

    Topics: Breast Neoplasms; Cell Survival; Chromones; Enzyme Inhibitors; Female; Glycogen Synthase Kinase 3; G

2012
Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1.
    Oncogene, 2013, Sep-12, Volume: 32, Issue:37

    Topics: Breast Neoplasms; Cell Transformation, Neoplastic; Chromones; Class Ia Phosphatidylinositol 3-Kinase

2013
Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
    Oncology reports, 2013, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chromones; Dose-Response Relationship, Dr

2013
Inhibition of rapamycin-induced Akt phosphorylation by cotylenin A correlates with their synergistic growth inhibition of cancer cells.
    International journal of oncology, 2013, Volume: 42, Issue:2

    Topics: Benzoquinones; Breast Neoplasms; Cell Proliferation; Chromones; Diterpenes; Drug Synergism; Female;

2013
Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2002, Volume: 11, Issue:5

    Topics: Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Differentiation; Chromones; DNA, Neoplasm; Dose

2002
Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Age

2002
Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western;

2002
Estradiol rapidly activates Akt via the ErbB2 signaling pathway.
    Molecular endocrinology (Baltimore, Md.), 2003, Volume: 17, Issue:5

    Topics: Androstadienes; Breast Neoplasms; Chromones; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha;

2003
Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:4

    Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Survival; Chromon

2003
Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells.
    The Journal of biological chemistry, 2003, Aug-01, Volume: 278, Issue:31

    Topics: Androstadienes; Breast Neoplasms; Cell Movement; Chromones; Enzyme Inhibitors; Gene Expression; Huma

2003
Akt promotes increased mammalian cell size by stimulating protein synthesis and inhibiting protein degradation.
    American journal of physiology. Endocrinology and metabolism, 2003, Volume: 285, Issue:5

    Topics: Animals; Breast Neoplasms; Cell Count; Cell Cycle; Cell Size; Chromones; Enzyme Activation; Insulin;

2003
Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line.
    The Journal of biological chemistry, 2003, Oct-31, Volume: 278, Issue:44

    Topics: Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Nucleus; Chromones; DNA-Binding Proteins; En

2003
Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
    Oncogene, 2003, Sep-11, Volume: 22, Issue:39

    Topics: Androstadienes; Antibodies; Breast Neoplasms; Cell Division; Cell Membrane; Chromones; Drug Resistan

2003
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12

    Topics: Breast Neoplasms; Chromones; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epiderma

2003
Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways.
    The Journal of steroid biochemistry and molecular biology, 2003, Volume: 86, Issue:3-5

    Topics: Adaptation, Physiological; Adaptor Proteins, Signal Transducing; Aromatase; Breast Neoplasms; Butadi

2003
Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells.
    The Journal of cell biology, 2004, Feb-16, Volume: 164, Issue:4

    Topics: Actins; Animals; Breast Neoplasms; Cell Culture Techniques; Cell Division; Cell Polarity; Chromones;

2004
Differential regulation of signal transduction pathways in wild type and mutated p53 breast cancer epithelial cells by copper and zinc.
    Archives of biochemistry and biophysics, 2004, Mar-15, Volume: 423, Issue:2

    Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Chromones; Copper; Cyclin D1; Cyclin-Depe

2004
Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility.
    The Journal of biological chemistry, 2004, Jun-04, Volume: 279, Issue:23

    Topics: Actins; Activin Receptors, Type I; Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Hum

2004
Deregulation of PKB influences antiapoptotic signaling by PKC in breast cancer cells.
    International journal of oncology, 2004, Volume: 25, Issue:3

    Topics: Apoptosis; Breast Neoplasms; Chromones; DNA; Humans; Indoles; Maleimides; Morpholines; Phosphorylati

2004
Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase.
    Molecular endocrinology (Baltimore, Md.), 2004, Volume: 18, Issue:11

    Topics: Animals; Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Cyclin A; Estradiol; Estrogens;

2004
[Overexpression of HER2/neu downregulates wild p53 protein expression via PI3K and Ras/Raf/MEK/ERK pathways in human breast cancer cells].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2004, Volume: 33, Issue:4

    Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Down-Regulation; Extracellular Signal-Reg

2004
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:10

    Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Cell Proliferation; Chromones; Enzyme Inh

2004
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:10

    Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Cell Proliferation; Chromones; Enzyme Inh

2004
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:10

    Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Cell Proliferation; Chromones; Enzyme Inh

2004
Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:10

    Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Cell Proliferation; Chromones; Enzyme Inh

2004
Insulin-like growth factor I controls adhesion strength mediated by alpha5beta1 integrins in motile carcinoma cells.
    Molecular biology of the cell, 2005, Volume: 16, Issue:1

    Topics: Actins; Amides; Blotting, Western; Breast Neoplasms; Butadienes; Carcinoma; Catalysis; Cell Adhesion

2005
Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy.
    Cell research, 2004, Volume: 14, Issue:6

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; Female; Genes, e

2004
[The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:10

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cesium Radioisotopes; Chromones; Female; Gen

2004
Prolactin and heregulin override DNA damage-induced growth arrest and promote phosphatidylinositol-3 kinase-dependent proliferation in breast cancer cells.
    International journal of oncology, 2005, Volume: 26, Issue:2

    Topics: Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival

2005
AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner.
    Molecular cancer research : MCR, 2005, Volume: 3, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromo

2005
In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: involvement of PI-3K/Akt and MEK1/ERK pathways.
    The Journal of pathology, 2005, Volume: 205, Issue:4

    Topics: Breast Neoplasms; Cell Line, Tumor; Chromones; Cycloheximide; DNA-Binding Proteins; Enzyme Inhibitor

2005
Protein kinase C zeta is required for epidermal growth factor-induced chemotaxis of human breast cancer cells.
    Cancer research, 2005, Feb-15, Volume: 65, Issue:4

    Topics: Alkaloids; Benzophenanthridines; Breast Neoplasms; Cell Line, Tumor; Chemokine CXCL12; Chemokines, C

2005
Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
    Breast cancer research and treatment, 2005, Volume: 91, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2005
Atypical PKC-zeta and PKC-iota mediate opposing effects on MCF-7 Na+/K+ATPase activity.
    Journal of cellular physiology, 2005, Volume: 205, Issue:2

    Topics: Androstadienes; Angiotensin II; Animals; Blotting, Western; Breast Neoplasms; Cattle; Cell Line, Tum

2005
Somatic mutation and gain of copy number of PIK3CA in human breast cancer.
    Breast cancer research : BCR, 2005, Volume: 7, Issue:5

    Topics: Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Chro

2005
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.
    Breast cancer research : BCR, 2005, Volume: 7, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cell Surviva

2005
Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.
    Acta pharmacologica Sinica, 2005, Volume: 26, Issue:10

    Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Breast Neoplasms; Butadienes; Carcinoma, Non-

2005
Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Breast cancer research and treatment, 2005, Volume: 93, Issue:2

    Topics: Blotting, Western; Breast Neoplasms; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival

2005
Inhibition of phosphatidylinositol 3-kinase/protein kinase B signaling is not sufficient to account for indole-3-carbinol-induced apoptosis in some breast and prostate tumor cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23

    Topics: Antioxidants; Apoptosis; Blotting, Western; Breast Neoplasms; Chromones; Drug Combinations; Enzyme I

2005
Protein kinase C (PKC)-delta/-epsilon mediate the PKC/Akt-dependent phosphorylation of extracellular signal-regulated kinases 1 and 2 in MCF-7 cells stimulated by bradykinin.
    The Journal of endocrinology, 2006, Volume: 188, Issue:1

    Topics: Analysis of Variance; Biological Transport; Bradykinin; Bradykinin B1 Receptor Antagonists; Bradykin

2006
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:1

    Topics: Androstadienes; Breast Neoplasms; Cell Extracts; Chromones; Enzyme Inhibitors; Female; Glycerylphosp

2006
Leptin receptor expression and cell signaling in breast cancer.
    International journal of oncology, 2006, Volume: 28, Issue:4

    Topics: Blotting, Western; Breast Neoplasms; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival

2006
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA-MB468 human breast cancer cells to cerulenin-induced apoptosis.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:3

    Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms;

2006
Insulin-like growth factor I differentially regulates the expression of HIRF1/hCAF1 and BTG1 genes in human MCF-7 breast cancer cells.
    International journal of molecular medicine, 2006, Volume: 18, Issue:1

    Topics: Amino Acid Sequence; Base Sequence; Blotting, Northern; Breast Neoplasms; Cell Line, Tumor; Chromone

2006
Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells.
    Cancer research, 2006, Dec-01, Volume: 66, Issue:23

    Topics: Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Cy

2006
Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells.
    The Journal of biological chemistry, 2007, Sep-07, Volume: 282, Issue:36

    Topics: 3' Untranslated Regions; 5' Untranslated Regions; Acetyl-CoA Carboxylase; Breast Neoplasms; Cell Lin

2007
Indole-3-carbinol-induced modulation of NF-kappaB signalling is breast cancer cell-specific and does not correlate with cell death.
    Breast cancer research and treatment, 2008, Volume: 109, Issue:3

    Topics: Anticarcinogenic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chromones; DN

2008
Basic FGF augments hypoxia induced HIF-1-alpha expression and VEGF release in T47D breast cancer cells.
    Pathology, 2007, Volume: 39, Issue:4

    Topics: Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Extracellular Signal

2007
Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.
    Breast cancer research and treatment, 2008, Volume: 112, Issue:2

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; Class I Phosphatidylinositol 3-Ki

2008
Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium.
    Life sciences, 2008, Feb-27, Volume: 82, Issue:9-10

    Topics: Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Chromones; Culture Media, Serum-Fr

2008
Retinoic acid stimulation of the sodium/iodide symporter in MCF-7 breast cancer cells is mediated by the insulin growth factor-I/phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase signaling pathways.
    The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:5

    Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; Cyclic AMP-Dependent Protein Kina

2008
Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase.
    The Journal of biological chemistry, 1997, Dec-05, Volume: 272, Issue:49

    Topics: Breast Neoplasms; Cell Division; Chromones; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin

1997
Insulin-stimulated cell growth in insulin receptor substrate-1-deficient ZR-75-1 cells is mediated by a phosphatidylinositol-3-kinase-independent pathway.
    Journal of cellular biochemistry, 1998, Aug-01, Volume: 70, Issue:2

    Topics: Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Cell Line, Transforme

1998
Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis.
    The Journal of cell biology, 1998, Oct-19, Volume: 143, Issue:2

    Topics: Androstadienes; Animals; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Cell Adhesi

1998
Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.
    Biochemical and biophysical research communications, 1999, Jul-14, Volume: 260, Issue:3

    Topics: Adenocarcinoma; Breast Neoplasms; Calcium-Calmodulin-Dependent Protein Kinases; Chromones; Epidermal

1999
Prolactin as a chemoattractant for human breast carcinoma.
    Endocrinology, 1999, Volume: 140, Issue:11

    Topics: Breast Neoplasms; Chemotactic Factors; Chemotaxis; Chromones; Cytoskeleton; Drug Synergism; Enzyme I

1999
Insulin-like growth factor I activates c-Jun N-terminal kinase in MCF-7 breast cancer cells.
    Endocrinology, 2000, Volume: 141, Issue:2

    Topics: Breast Neoplasms; Chromones; Enzyme Activation; Enzyme Inhibitors; Female; Flavonoids; Genes, Report

2000
Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:1

    Topics: Androstadienes; Animals; Antibodies, Monoclonal; Breast Neoplasms; Cell Cycle; Chromones; Dimerizati

2000
Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells.
    Molecular endocrinology (Baltimore, Md.), 2000, Volume: 14, Issue:2

    Topics: Androstadienes; Breast Neoplasms; Chromones; Enzyme Inhibitors; Female; Flavonoids; Gene Expression

2000
Inhibition of mitogen-activated protein kinase and phosphatidylinositol 3-kinase activity in MCF-7 cells prevents estrogen-induced mitogenesis.
    Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research, 2000, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Androstadienes; Breast Neoplasms; Butadienes; Chromones; Culture Media, Serum-Free;

2000
Anchorage-independent activation of mitogen-activated protein kinase through phosphatidylinositol-3 kinase by insulin-like growth factor I.
    Biochemical and biophysical research communications, 2000, May-27, Volume: 272, Issue:1

    Topics: Breast Neoplasms; Cell Adhesion; Chromones; DNA, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Fem

2000
Differential signaling by an anti-p185(HER2) antibody and heregulin.
    Cancer research, 2000, Jul-01, Volume: 60, Issue:13

    Topics: Antibodies, Monoclonal; Breast Neoplasms; Cell Cycle; Chromones; Enzyme Inhibitors; Estrenes; Female

2000
Stabilization of cyclin D1 mRNA via the phosphatidylinositol 3-kinase pathway in MCF-7 human breast cancer cells.
    The Journal of endocrinology, 2000, Volume: 166, Issue:2

    Topics: Blotting, Northern; Blotting, Western; Breast Neoplasms; Chromones; Cyclin D1; Enzyme Inhibitors; Ep

2000
Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells.
    Oncogene, 2000, Sep-21, Volume: 19, Issue:40

    Topics: Alkaline Phosphatase; Biological Transport; Breast Neoplasms; Cell Nucleus; Chromones; Cytoplasm; DN

2000
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.
    The Journal of biological chemistry, 2001, Mar-30, Volume: 276, Issue:13

    Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Divis

2001
Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
    Cancer research, 2001, Feb-15, Volume: 61, Issue:4

    Topics: Benzoquinones; Breast Neoplasms; Cell Movement; Chromones; Enzyme Inhibitors; Flavonoids; Gene Expre

2001
PTEN expression causes feedback upregulation of insulin receptor substrate 2.
    Molecular and cellular biology, 2001, Volume: 21, Issue:12

    Topics: Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line; Chromones; Enzyme Inhibitors; Feedback; Female;

2001
Ezrin is a downstream effector of trafficking PKC-integrin complexes involved in the control of cell motility.
    The EMBO journal, 2001, Jun-01, Volume: 20, Issue:11

    Topics: Amino Acid Substitution; Breast Neoplasms; Cell Membrane; Cell Movement; Chromones; Cytoskeletal Pro

2001
Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells.
    Cancer research, 2001, Aug-01, Volume: 61, Issue:15

    Topics: Apoptosis; Breast Neoplasms; Cell Hypoxia; Cell Survival; Chromones; Endothelial Growth Factors; Enz

2001
Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
    Cancer research, 2001, Oct-01, Volume: 61, Issue:19

    Topics: Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Breast Neoplasms; Carcinoma, Renal

2001
Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator.
    The Journal of biological chemistry, 2002, Feb-01, Volume: 277, Issue:5

    Topics: Androstadienes; beta-Galactosidase; Breast Neoplasms; Cell Movement; Chloramphenicol O-Acetyltransfe

2002
CRBP suppresses breast cancer cell survival and anchorage-independent growth.
    Oncogene, 2001, Nov-01, Volume: 20, Issue:50

    Topics: Agar; Apoptosis; Breast; Breast Neoplasms; Carrier Proteins; Cell Adhesion; Cell Division; Cell Line

2001
ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth.
    Oncogene, 2001, Nov-08, Volume: 20, Issue:51

    Topics: Androstadienes; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Adhesion; Cell Division; Cell Su

2001
Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer.
    Breast cancer research and treatment, 2001, Volume: 70, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Butadienes; Chromones; Down-R

2001
Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells.
    Oncogene, 2002, Mar-27, Volume: 21, Issue:13

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Breast Neoplasms; Cell Su

2002
AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival.
    Oncogene, 2002, May-16, Volume: 21, Issue:22

    Topics: Androstadienes; Apoptosis; Breast Neoplasms; Carcinoma; Cell Hypoxia; Cell Survival; Chromones; Enzy

2002
Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells.
    Biochemical and biophysical research communications, 2002, Jun-07, Volume: 294, Issue:2

    Topics: Androstadienes; Breast Neoplasms; Cell Division; Chromones; DNA-Binding Proteins; Enzyme Inhibitors;

2002
Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer.
    Clinical & experimental metastasis, 2002, Volume: 19, Issue:4

    Topics: Adenocarcinoma; ADP Ribose Transferases; Botulinum Toxins; Breast Neoplasms; Chromones; Endothelial

2002